Biogen Inc., BIIB is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Biogen Inc., BIIB has a market cap of 68271.18. Since its IPO date on the 9/17/1991, Biogen Inc., BIIB performance year to date is -2.14%. Today Biogen Inc., BIIB has gained -0.47%, with a current price of 298.39.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 88.30%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 18.50%, with return on investment at 23.50%.
In terms of debt levels and profit levels, Biogen Inc., BIIB is seeing a long-term debt/equity of 0.57. While Total debt/equity is 0.57. With a profit margin of 34.00%, this is combined with a gross margin of 88.20%, and operating margin of 47.90%. Biogen Inc. ability to meet debt levels, with a current ratio of 3, while the quick ratio is 2.6.
For the last year Biogen Inc., BIIB has seen a EPS growth of 24.00%. A performance for the year of -6.27%. The 52-week high is -10.57%, and the 52-week low is 33.80%. The average volume for Biogen Inc., BIIB is 88820.
With a target price of 342.28, can Biogen Inc., BIIB reach this target? Looking at the value indicators of Biogen Inc., BIIB. Biogen Inc. has a P/E of 17.5 and a forward P/E of 14.44. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.84. Biogen Inc. also has a P/S and a P/B of 6.07 and 5.76 respectively. For P/cash, Biogen Inc. has a value of 17.98, while it is 21.23 for P/free cash flow.
At the current price of 298.39, Biogen Inc. has a dividend yield of *TBA. We see a return on equity of 36.60%.
Looking more long-term Biogen Inc., is projected to get an EPS growth for the next five years of 9.50%. In the short-term an EPS growth of 3.31% in the next year is forecasted. This is after a EPS growth of 24.00% for this year and for the last five years a 31.30% growth has been seen.